Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141414 · ClinicalTrials.gov registry record · Phase 2
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
A Phase 2 study of Epilepsy, Partial, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 20
- Study locations
NCT00141414 is a Phase 2 study of Epilepsy, Partial that has completed, run by Pfizer. The registered enrollment target is 82 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT00141414, a Phase 2 study of Epilepsy, Partial, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the long-term safety of pregabalin in refractory partial epilepsy.
Conditions Studied
Interventions
- DRUG Pregabalin
Study Locations (20)
New York
- Pfizer Investigational Site - New York
- Pfizer Investigational Site - New York
- Pfizer Investigational Site - Rochester
- Pfizer Investigational Site - The Bronx
California
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Stanford
Florida
- Pfizer Investigational Site - Miami
- Pfizer Investigational Site - Plantation
Indiana
- Pfizer Investigational Site - Indianapolis
- Pfizer Investigational Site - Indianapolis
Maryland
- Pfizer Investigational Site - Baltimore
- Pfizer Investigational Site - Baltimore
Ohio
- Pfizer Investigational Site - Cleveland
- Pfizer Investigational Site - Columbus
Arkansas
- Pfizer Investigational Site - Little Rock
Massachusetts
- Pfizer Investigational Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 1997-11 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00141414
The ClinicalTrials.gov registry entry for NCT00141414 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy, Partial appearing as the primary indexed condition, and to 1 intervention - of which Pregabalin is the first listed.
NCT00141414 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00141414 about?
NCT00141414 is a clinical study titled "To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.". To evaluate the long-term safety of pregabalin in refractory partial epilepsy.
What is the current status of trial NCT00141414?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 1997-11. Estimated completion is 2005-10.
What conditions does trial NCT00141414 study?
This clinical trial studies the following conditions: Epilepsy, Partial.
What interventions are being tested in trial NCT00141414?
The interventions under investigation include: Pregabalin (DRUG).
Who is sponsoring clinical trial NCT00141414?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00141414 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy, Partial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.